Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients

J. Garde Noguera,P. Martin Martorell,M. De Julian,J. Pérez Altozano,C. Salvador Coloma,José García Sánchez,A. Insa Molla,María Martín,X. Mielgo Rubio,S. Marin-Liebana,A Blasco Cordellat,S. Blasco Mollá,Regina Gironés,D. Márquez Medina,F. Aparisi,M. C. Bas Cerda,S. Maciá Escalante,Alejandro Ferrando Sánchez,O. Juan-Vidal

Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients

2018

J. Garde Noguera
P. Martin Martorell
M. De Julian
J. Pérez Altozano
C. Salvador Coloma
José García Sánchez
A. Insa Molla
María Martín
X. Mielgo Rubio
S. Marin-Liebana
A Blasco Cordellat
S. Blasco Mollá
Regina Gironés
D. Márquez Medina
F. Aparisi
M. C. Bas Cerda
S. Maciá Escalante
Alejandro Ferrando Sánchez
O. Juan-Vidal

Background Immunotherapy increases overall response rate (ORR) and overall survival (OS) in patients with non-small-cell lung cancer (NSCLC). Prognostic and predictive factors are a high need.

Keywords:

General surgery
Nivolumab
Lung cancer
Immunotherapy
Medicine
Survival rate
Oncology
Internal medicine
Pathology
non small cell
in patient
Pathological
Retrospective cohort study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations